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Mineralization, a characteristic phenotypic
property of osteoblastic lineage cells, was
blocked by AEBSF and dec-RRLL-cmk,
inhibitors of SKI-1 (site 1; subtilisin kexin like1) protease. Since SKI-1 is required for
activation of SREBP and CREB/ATF family
transcription factors, we tested the effect of
these inhibitors on gene expression. AEBSF
decreased expression of 140 genes by 1.5- to 3.0fold including Phex, Dmp1, COL1A1, COL11A1
and fibronectin. Direct comparison of AEBSF
and dec-RRLL-cmk, a more specific SKI-1
inhibitor, demonstrated that expression of
Phex, Dmp1, COL11A1 and fibronectin was
reduced by both while COL1A2 and HMGCS1
were reduced only by AEBSF. AEBSF and decRRLL-cmk decreased the nuclear content of
SKI-1 activated forms of transcription factors
SREBP-1, SREBP-2, and OASIS. In contrast
to AEBSF, the actions of dec-RRLL-cmk
represent the sum of its direct actions on SKI-1
and indirect actions on caspase-3. Specifically,
dec-RRLL-cmk reduced intracellular caspase-3
activity by blocking the formation of activated
19 kDa caspase-3. Conversely, over-expression
of SKI-1 activated SREBP-1a and CREB-H in
UMR106-01 osteoblastic cells increased the
number of mineralized foci and altered their
morphology to yield mineralization nodules,
respectively. In summary, SKI-1 regulates the
activation of transmembrane transcription
factor precursors required for expression of
key genes required for mineralization of
osteoblastic cultures in vitro and bone

formation in vivo. Our results indicate that the
differentiated phenotype of osteoblastic cells,
and possibly osteocytes, depends upon the nonapoptotic actions of SKI-1.
Bone formation and mineralization is a multistep process of differentiated osteoblastic cells.
Based upon an analysis of gene expression during
osteogenesis, Lian and Stein (1) noted that ―peak
levels of expressed genes reflect a developmental
sequence of bone cell differentiation characterized
by three principal periods: proliferation,
extracellular matrix maturation and mineralization,
and two restriction points to which the cells can
progress but cannot pass without further signals.‖
These authors defined these three periods of
osteoblastic differentiation in terms of patterns of
sequential gene expression.
For example,
fibronectin and type I collagen expression denoted
the pattern of pre-osteoblastic cells, alkaline
phosphatase and MGP6 reflected the matrix
maturation stage, and, osteopontin and osteocalcin
reflected the mineralization stage of mature
osteoblastic cells (1). However, the number of
genes required for normal bone formation and
mineralization has grown rapidly to include Phex
(Phex), dentin matrix protein1 (Dmp1), and type
XI collagen (COL11).
Phex (phosphate regulating endopeptidase
homolog, X-linked) is a transmembrane
metalloendoprotease enriched on bone osteoblasts
and osteocytes (2). It is essential for phosphate
homeostasis and bone mineralization since loss of
function
mutations
result
in
X-linked
hypophosphatemic
rickets
(3).
Acidic
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phosphorylated dentin matrix protein 1 is highly
expressed in teeth and osteocytes in bone.
Mutations in Dmp1 cause autosomal recessive
hypophosphatemic rickets (4, 5). Elevated
circulating levels of fibroblast growth factor 23 are
a characteristic shared by both this human
condition and by mice lacking Dmp1 (5). The
hypophosphatemic rickets and elevated FGF23
levels that occur in Dmp1 null mice resemble the
‗hyp‘ mouse, which has an inactivating mutation
in Phex. Since skeletal abnormalities in both these
animal models can be largely but not completely
rescued by feeding a high phosphate diet, DMP1
and Phex regulate an essential pathway controlling
serum phosphate levels needed for mineralization
of teeth and bone. Type XI collagen regulates the
rate of fibrillogenesis of type I and II collagen and
the ultimate size of fibrils (6). Homozygous cho
mice containing a frame shift mutation in the
COL11A1 gene die at birth with severe
abnormalities of bone and tracheal cartilage (7). In
humans, COL11A1 mutations cause Marshall and
Stickler syndromes (8) characterized by
craniofacial abnormalities, nearsightedness and
hearing deficiencies. Finally, fibronectin is a
multi-functional matrix organizing protein
possessing
binding
sites
for
collagen,
glycosaminoglycan chains, and cell adhesion
receptors. Blocking antibodies against the
fibronectin receptor inhibit the mineralization of
osteoblastic cells in culture (9-11). Although
genetic knockouts and mutations causing skeletal
abnormalities have identified these and other
genes, detailed mechanisms controlling bone
formation and mineralization are incompletely
understood.
We have used osteoblastic culture models to
investigate the mechanism controlling bone
mineralization (12-18).
Mineralization occurs
within spherical, macromolecular, extracellular,
vesicle-enriched
complexes
termed
biomineralization
foci.
Since
BMF
phosphoprotein biomarkers can be used to define
areas of growing periosteum and developing
fracture callus prior to their mineralization (14,
15), osteoblastic cultures appear to model bone
formation in vivo. Proteomic analyses on laser
micro dissected mineralized BMF show they are
enriched in phosphoproteins BSP and BAG-75 and
their
fragments.
Interestingly,
both
phosphoprotein cleavage and mineralization of
BMF can be completely blocked with covalent
serine protease inhibitor AEBSF, whereas 15 other

inhibitors against acidic, metallo-, and sulfhydryl
proteases were without effect (16). Based on these
results, we hypothesized that initiation of bone
mineralization is controlled by a serine protease.
We recently showed that BMF contained an
active, 105 kDa form of SKI-1 protease (18).
SKI-1 is a member of the proprotein
convertase family (19). PCs, serine proteases
related to bacterial subtilisin and yeast kexin,
cleave and activate growth factors, neuropeptides,
toxins, glycoproteins, viral capsid proteins, and
transcription
factors.
Transmembrane
transcription factor precursors SREBP-1 and -2 are
activated in a sequential process involving first
SKI-1 cleavage and then S2P protease cleavage
(20). SREBPs can also be activated by caspase-3
(21, 22). The N-terminal fragments of SREBP-1
and SREBP-2 can then be imported into the
nucleus where each regulates gene expression by
binding to promoters containing consensus SRE
sequences (23). Members of the CREB/ATF
family of transcription factors [ATF-6, LUMAN
(CREB3), OASIS/BBF2H7 (CREB3L2), CREBH, CREB-4, and AIbZIP/Tisp40 (CREB3L4)] also
require SKI-1 catalyzed activation. By activating
ATF-6, SKI-1 serves as an initiator of the
unfolded protein response which decreases cellular
stress by increasing chaperone production,
influencing ER-associated degradation of proteins,
and regulating membrane remodeling (24).
Recent studies indicate that SKI-1 is required
for normal bone formation. First, the skeletons of
mice deficient in OASIS (25) exhibit a severe
osteopenia characterized by a type I collagendeficient bone matrix and reduced osteoblastic
activity (26). Second, mice over-expressing ICER,
a dominant negative effector of CREB/ATF
transcription factors, displayed dramatically
reduced trabecular bone and a reduced femoral
bone formation rate (27). Third, SKI-1 is required
for normal cartilage morphogenesis in zebrafish
(28). Finally, conditional inactivation of SKI-1 in
mice using a type II collagen Cre recombinase
transgene leads to abnormal growth plate
calcification (29).
The purpose of this study was to determine
whether SKI-1 protease controls initiation of
osteoblastic mineralization.
EXPERIMENTAL PROCEDURES
Growth, mineralization and treatment of UMR
cells with protease inhibitors. UMR 106-01 BSP
cells were passaged and cultured as described
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previously (12). Cells were seeded at a density of
1.0 x 105 cells/cm2 in Growth Medium. After 24
h, Growth Medium containing 0.5% BSA
(Millipore #82-045-1) was exchanged for FBS
containing medium. Sixty-four hours after plating,
spent medium was exchanged with Mineralization
Media (Growth Medium containing 0.1% BSA
and 6.5 mM BGP). Addition of a supplemental
phosphate source to UMR 106-01 cultures prior to
64 h had no effect on the formation of mineral
crystals (Midura and Gorski, manuscript in
preparation). Cultures were then incubated for up
to an additional 24 h at which time they were fixed
with 70% ethanol.
In some experiments, serine protease inhibitor
AEBSF (EMD Biosciences, Inc.) or dec-RRLLcmk (Bachem, Inc.) was added over a range of
concentrations in Mineralization Media at 64 h
after plating. We have shown previously (16) that
100 µM AEBSF is the minimum dosage able to
effectively block mineralization of BMF within
serum-depleted UMR cultures.
The extent of mineralization was either
assessed visually by fluorescence microscopy
(after staining with 10 µg/ml Alizarin red S dye)
or quantitated by colorimetric calcium assay (17)
by reference to a standard curve. In the latter case,
calcium was first extracted from culture wells with
acidified 70% ethanol and the extracts were then
concentrated prior to analysis.
Transgenic DMP1 GFP mice were kindly
provided by Drs. I. Kalajzic and D.W. Rowe,
University of Connecticut Health Center.
SDS gel electrophoresis and Western blotting.
Protein samples were electrophoresed under
reducing conditions on 4-20% linear gradient gels
(Pierce Chem. /Thermo Scientific) according to
Laemmli (30) and electro blotted onto PVDF
membranes (Millipore Corp.) for 1.5-2 h at 100
volts in 10 mM CAPS buffer (pH 11.0) containing
10% methanol.
Blots were processed with
primary antibody and horseradish peroxidaseconjugated secondary antibody as described
previously (17) and chemiluminescent digital
images captured with a Fuji LAS-4000.
Anti-SKI-1 antibodies [h-SKI-CT (C-terminal
specific for aa 1036-1051); 723.03 (recognizes
pro-SKI-1); 705.02 (recognizes residues 634-651)]
[see Pullikotil et al. (31, 32) for details] and antiCREB-H antibodies (33) were a gift from Dr. K
Zhang, Wayne State Univ. Antibodies against
SREBP-1 (aa 38-89), SREBP-2 (aa 424-473), and
GAPDH were purchased from Sigma Chemical

Inc. while antibodies against OASIS were
obtained from Aviva Systems Biology.
Isolation of nuclear and cytoplasmic fractions
from UMR 106-01 cultures. UMR 106-01 cells
were cultured under serum depleted conditions as
described above. Sixty-four hours after plating,
the medium was exchanged for Mineralization
Medium (18); some of the cultures were also
treated with 100 µM AEBSF, 40 µM dec-RRLLcmk, 10 µM Z-DEVD-fmk or 20 µM Z-DEVDfmk. Cultures were then incubated for an
additional 12 hours and then the nuclear and
cytoplasmic fractions were prepared using a
Thermo Scientific NE-PER Nuclear and
Cytoplasmic Extraction kit per the manufacturer‘s
instructions. Extracts were aliquoted and stored at
-80°C until subjected to Western blotting.
Transfection with plasmids. UMR 106-01 cells
were plated in 24 well plates with Growth Medium
containing 10% FBS. At 40 h after plating,
transfections were carried out in Growth Medium
containing 1% FBS. Initially, each plasmid was
pre-titered to determine an optimum dosage; cell
cultures were transfected with 0.25-0.75 µg of
plasmid DNA at three different levels of
Metafectene Pro transfection reagent (Biontex) per
manufacturer‘s protocol. Individual plasmids and
Metafectene Pro reagent were pre-incubated at
room temperature for 20 minutes prior to addition
to cells for 24 hrs at which time the mixture was
exchanged for serum-free Mineralization Medium
containing 0.1% BSA. An optimized dosage of
plasmid was used in subsequent studies examining
the effect of over-expression of recombinant
transcription factors on mineralization. At 88 hrs
after plating, cultures were fixed in 70% ethanol
and then stained with 10 µg/ml Alizarin red S dye.
Both bright field and fluorescence microscopic
images were obtained. Alternatively, calcium was
quantitated with a colorimetric assay (16).
Expression plasmids were prepared as follows.
cDNAs coding for hSREBP-1a, -1c and -2 were
purchased from Origene. PCR was used to clone
their N-terminal fragments and to then tag them
with the V5 epitope (GKPIPNPLLGLDST) at
their C-terminus. The resultant plasmids produced
the following proteins: hSREBP1a = aa 1-511V5; SREBP-1c = aa 55-511-V5; and, SREBP-2 =
aa 1-475-V5.
[Expression plasmids OASIS
TMC-HA tag, OASIS TMC, and CREB-H TMC
were kindly provided by Dr. P. O`Hare (Marie
Curie Research Institute, United Kingdom)].
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Extraction of proteins from UMR 106-01 cultures.
UMR 106-01 cells were seeded in 48-well plates
and grown in serum depleted conditions as
described previously (16, 17). During the final 24
h mineralization period, wells were exchanged
with Mineralization Medium containing 0.1%
BSA; some of the wells also received 100 µM
AEBSF or 40 µM dec-RRLL-cmk. At the
conclusion of the culture period, media was
removed, inactivated at 95°C for 5 min, dialyzed
against 5% acetic acid, and lyophilized to dryness.
The cell layer was extracted as previously
described (16); EDTA extracts were immediately
inactivated at 95 and processed as described
above.
Subsequent Urea/CHAPS cell layer
extracts (16) were homogenized and then
ultracentrifuged at 30,000 rpm (~100,000 x g) for
1 h in an SW50.1 rotor prior to SDS PAGE and
Western blotting studies.
Laser micro dissection of BMF. UMR 106-01
cells were plated onto glass slides, mineralized,
and processed for laser micro dissection,
extraction and Western blotting as described by
Huffman et al. (16).
Primary calvarial cell isolation and cell culture.
Primary mouse osteoblasts were isolated from
calvaria of 5- to 7-day-old transgenic DMP1 GFP
mice (34) using a modification of a published
method (35, 36). Briefly, four sequential 20-min
digests were performed in Hanks' balanced salt
solution containing 0.05% trypsin and 0.2%
collagenase. Fractions 2 to 4 were pooled,
centrifuged, and re-suspended in α-MEM medium
containing 10% FBS, 2 mM L-glutamine, 100
units/ml penicillin, and 30 μg/ml gentamicin (αGrowth Medium). 2 × 106 cells were plated per T75-cm2 flask and allowed to reach confluency.
Flasks were then trypsinized and the cells plated
onto 48-well culture dishes. At confluency, the
media was changed to α-MEM containing 5%
FBS, 50 μg/ml ascorbic acid, 5 mM betaglycerolphosphate, and antibiotics. BGP was
omitted from wells that served as un-mineralized
controls.
Some cultures were treated on days 6 and 9
with 8 μM dec-RRLL-cmk or 10 µM AEBSF. On
day 12, cultures were either incubated with MTT
or were fixed with 2% p-formaldehyde and
processed for Alizarin red S staining. Images
were taken with a Nikon T2000 fluorescence
microscope equipped with a CCD camera.
DNA array. Triplicate UMR 106-01 cultures were
plated (13, 16) and grown with or without 400 µM

AEBSF for 12 h prior to isolation of total RNA
(~5 g) and then converted to single stranded
cDNA using Superscript II reverse transcriptase
(InVitrogen, Inc.) and the Gene Chip T7 promoter
primer kit. [Note: the minimum effective dose of
AEBSF capable of completely blocking
mineralization in UMR 106-01 cultures is 100 µM
in serum free media and 400 µM in media
containing 10% FBS (16)]. Single stranded cDNA
was then converted to double stranded cDNA
using DNA polymerase I DNA ligase and RNase
H from E. coli. The double stranded cDNA was
purified using a cleanup kit from Affymetrix and
converted to biotinylated cRNA by in vitro
transcription using T7 polymerase and biotinylated
ribonucleotides
(Affymetrix).
This
was
subsequently fragmented by metal induced
hydrolysis to yield 35-200 base fragments that
were hybridized to the Affymetrix Rat Genome
230 Plus 2.0 oligonucleotide arrays. After
hybridization, the chip was washed and stained
with streptavidin-phycoerythrin before being
scanned. An antibody amplification staining
protocol that used biotinylated goat IgG followed
by a second SAPE staining increased the
sensitivity of the assay. The chip was then scanned
and images analyzed qualitatively using
Affymetrix Gene Chip Operating System
Software.
Microarray data analysis. CEL data files were
imported into Gene Spring GX software (v10) and
the data was normalized using either the MAS5 or
the GCRMA algorithm. The gene list was filtered
to exclude those which showed low signal values
across all samples (i.e. bottom 20th percentile).
Selection of statistically significant genes from
each expression profile was done using an
unpaired t-test with a p-value cut off of < 0.05.
The multiple testing correction (Benjamini and
Hochberg false discovery rate, p-value <0.05) was
integrated within each test. Differential expression
was defined as ≥1.5-fold change in expression
found using both MAS5 and GCRMA analysis.
Using this stringent criteria avoids false positives
associated with use of MAS5 alone as well as well
as facilitates the ability of GCRMA to account for
non-specific hybridization related background
signal.
Isolation of RNA from serum depleted osteoblastic
cultures and conversion to cDNA. UMR 106-01
cells were plated and grown under serum depleted
conditions (13, 16). At 64 h after plating, the
media
was
exchanged
with
serum-free
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Mineralization Media. At 76 h after plating,
media was removed from each well and cells were
quickly lysed with STAT-60 (Tel-Test, Inc.); the
lysates were then immediately frozen and stored in
liquid nitrogen vapor. Total RNA was isolated
according to manufacturer's instructions (Tel-Test,
Inc.). Each RNA pellet was washed 2 times with
80% ethanol and then air dried prior to resuspending in 10 µl RNase-free water containing
4% RNAsin inhibitor (Promega, Inc.).
cDNA
was produced using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems)
and stored frozen in aliquots.
For real time PCR, cDNA preparations were
diluted and added to 96-well plates containing
Taqman Master Mix solution and either the
appropriate FAM-(6-carboxyfluorescein)-labeled
expression gene primer set or the VIC-labeled actin control primer set (ABI, Inc.). Plates were
run on an ABI 7000 Real Time system using preprogrammed software.
All calculations were
made by the Delta-Delta CT method by
comparison to the -actin control.
Assay of Caspase-3. Recombinant caspase-3
(Sigma Chem. Co.) and lysates of UMR106-01
cultures were assayed using a fluorescent substrate
and reagents from Ana-Spec, Inc. (#71118)
according to the manufacturer‘s protocol.
Assay of SKI-1 Peptidase Activity. UMR106-01
cultures were cultured as usual in 48-well plates
and treated with inhibitors as described above.
The media was exchanged for serum-free medium
and then the total cell layer was disrupted by
scraping into reaction buffer and aliquots were
immediately assayed using a succinylated
TISRRLL-MCA substrate (37) and a fluorescent
plate reader at 0, 0.5, 1, and 2 h. Rates were
extrapolated from kinetic reaction curves.

the distribution of SKI-1 within mineralizing
cultures.
Mineralized BMF were isolated by laser micro
dissection from UMR 106-01 cultures and
Western blotted with a polyclonal antibody
recognizing the C-terminal cytosolic tail of SKI-1
(32). Only the 105 kDa form was present in BMF
isolated from mineralized cultures (lane BMF, Fig.
1A). In contrast, the CL-Min and CL-UnMin
lanes contained the 105 kDa band along with
presumed fragments at 70 and 50 kDa (Fig. 1A).
However, the 70 and 50 kDa components were not
detected in micro dissected BMF. While the BMF
fraction contains only mineralized foci (Fig. 1)
(16), CL-Min and CL-UnMin fractions represent
extracts of the cell layer from mineralized and unmineralized cultures, respectively, which includes
cells and BMF.
Cell layers were extracted with a two step
protocol devised to efficiently extract proteins
from cells and the extracellular matrix. Mild
EDTA
extraction
predominantly
removes
materials associated with extracellular BMF
complexes, whereas extraction with 8M
urea/CHAPS recovers residual intracellular and
extracellular matrix components (16). Activated
105 kDa SKI-1 was present in the EDTA extract
but absent from AEBSF-treated or un-mineralized
cultures (Fig. 1B) suggesting transport of SKI-1 to
extracellular
BMF
occurs
only
during
mineralization. Urea/CHAPS extracts contained
similar amounts of 105 kDa SKI-1 regardless of
the culture condition. The culture media contained
145 kDa SKI-1 precursor and a 50 kDa fragment
band. Due to the specificity of the antibody and
the structure of SKI-1 (31, 32, 38, 39), we assume
that all forms detected (145, 105, 70, and 50 kDa)
contain the transmembrane sequence and are
associated with membranes or vesicles released
from cells. Interestingly, the amount of 50 kDa
band in the media was found to be lower in
mineralized cultures indicating that breakdown of
SKI-1 may be increased under non-mineralizing
conditions (Fig. 1B).
Treatment of osteoblastic cultures with a specific
SKI-1 inhibitor also blocks mineralization. The
structure of dec-RRLL-cmk is based on the
preferred substrate specificity of SKI-1 and is
more specific than AEBSF (32, 37, 38). When
UMR106-01 cells were treated with dec-RRLLcmk, mineralization was progressively blocked as
the concentration of inhibitor was increased (Fig.
2A). Forty micromolar dec-RRLL-cmk represents

RESULTS
Activated 105 kDa form of SKI-1 is present in
biomineralization foci.
SKI-1 protease is
synthesized as a membrane bound precursor of
145 kDa (38) and is activated by autolytic
cleavage to generate catalytically active 105 kDa
(membrane bound) and 98 kDa (shed) forms (38,
39). SKI-1 can be inactivated by the irreversible
covalent serine protease inhibitor AEBSF. Since
we showed previously that AEBSF blocked
mineralization and inhibited fragmentation of
BMF biomarkers BSP and BAG-75 (16), we asked
if active SKI-1 is associated with extracellular
biomineralization foci and whether AEBSF alters
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a minimum effective inhibitory dose compared
with 100 µM AEBSF (Fig. 2A and B) (16). By
contrast, a structurally similar furin inhibitor (40),
dec-RVKR-cmk, was without effect (Fig. 2C).
Importantly, assays of treated cultures also
demonstrated that AEBSF and dec-RRLL-cmk
significantly decreased SKI-1 peptidase activity by
about 30 and 40%, respectively, while treatment
with other inhibitors containing analogous reactive
functional groups were without a negative effect
(Table 1). AEBSF and dec-RRLL-cmk do not
significantly decrease cell number (Fig 1) (16),
while Z-DEVD-OPH and dec-RVKR-cmk reduce
cell viability by no more than 15% (not shown).
We also treated primary calvarial osteoblastic
cultures from transgenic DMP1-GFP mice (34-36)
with dec-RRLL-cmk.
Since GFP expression
precedes mineralization in these cultures, this
protein serves as a marker of where and when
mineralization will occur in these longer term
cultures. Osteoblastic precursors were plated onto
collagen coated wells and grown under
mineralizing conditions for up to 12 days in the
presence of either 0, 1, or 8 µM dec-RRLL-cmk.
Concentrations of AEBSF and dec-RRLL-cmk
were lowered to accommodate the longer exposure
with primary cells versus UMR 106-01 cells.
Mineral crystals were detected by staining with
Alizarin red S and correlated with GFP expression.
Focal areas of GFP-positive cells generally
appeared about 6-8 days after plating and go on to
form mineralized nodules by about day 12 (Fig.
3A). Exposure to 8 µM dec-RRLL-cmk inhibitor
diminished expression of the DMP1-GFP reporter
(Fig. 3B), as well as blocking mineralization. As
a positive control, 10 µM AEBSF also completely
blocked mineralization and DMP1-GFP reporter
expression by primary calvarial cultures (16) (Fig.
3C). These results indicate that SKI-1 is required
for progression through the osteoblastic
mineralization stage and the transition to the
embedded osteoblast or osteocyte stage.
Short-term treatment of osteoblastic cells with
AEBSF decreases transcription of mineralizationrelated genes. Since SKI-1 and S2P catalyze the
release of activated transcription factors from the
cis/medial Golgi (19), we asked whether AEBSF
blocks transcription of mineralization related
genes. UMR106-01 cultures were treated for 12 h
(from
64-76
h
after
plating)
with or without a minimum concentration of
AEBSF sufficient to block mineralization.
UMR106-01 cultures begin to nucleate calcium

phosphate crystals within biomineralization foci at
76 h (16, 17). Total RNA was isolated, converted
to cDNA prior to labeling and incubated with
whole rat genome arrays (see EXPERIMENTAL
PROCEDURES for details).
AEBSF treatment reduced expression of 140
genes by 1.5 to 3-fold while twenty-eight genes
were found to be increased by at least 1.5-fold
[Array data has been deposited with the Gene
Expression Omnibus database (series accession
number GSE21476)]. It is noteworthy that genes
encoding a number of mineralization related
extracellular matrix proteins were reduced (Table
2), e.g., DMP1, type I procollagen alpha 1 and
alpha 2 chains, type XI procollagen alpha 1 chain,
fibronectin,
matrilin
3,
ectonucleotide
pyrophosphatase/phosphodiesterase 2 and 3, and
tenascin-C and -N. Interestingly, the reduced
expression for DMP1 observed (Table 2) is
consistent with the lack of DMP1-GFP transgene
expression noted in primary calvarial cultures
treated with these inhibitors (Fig. 3).
Dec-RRLL-cmk also blocks transcription of Dmp1,
Phex, FN1, COL11A1 genes. Because dec-RRLLcmk is a more specific inhibitor of SKI-1 than
AEBSF (20), we predicted that it should reproduce
those actions of AEBSF (Table 2) which are
mediated by SKI-1. To test this, UMR106-01
cultures were again treated for 12 h with 40 µM
dec-RRLL-cmk (Fig. 2). Parallel cultures were
also treated with AEBSF (16) (Fig. 2B). This
study was carried out under conditions of serum
deprivation to reduce exposure to cholesterol
which inhibits SCAP-mediated transport of
SREBPs towards the cis/medial Golgi where they
are activated by SKI-1 and S2P (41). We showed
earlier that the amount of mineral deposited in
UMR106-01 cultures is unaffected by serum
depletion (16).
Total RNA was isolated and converted to
cDNA. Quantitative PCR was then carried out on
a representative group of genes decreased by
AEBSF (Table 2). Expression of HMG-CoA
synthase (HMGCS1) was also included as a
positive control since it is regulated by SREBP
transcription factors activated by SKI-1 (42, 43).
Other cultures were treated with inhibitors until 88
h when the amount of mineralization was
determined. As expected, both inhibitors blocked
mineralization by greater than 90% (data not
shown but similar to that in Figure 2B).
All qPCR results are plotted in Figure 4 as a
percentage of the expression in cultures treated
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with mineralizing conditions. Visual inspection of
the data reveals two patterns. First, expression of
DMP1, procollagen XI alpha 1 chain, Phex, and
fibronectin was significantly decreased by each
SKI-1 inhibitor (Figs. 4A-D). For each gene, the
average knockdown with AEBSF was found to be
quantitatively greater than that for dec-RRLL-cmk
(Figs. 4A-D), but differences were not significant.
In the second pattern, highest expression of COL1
A2 and HMGCS1 occurred in dec-RRLL-cmk
treated cultures whereas that for mineralizing
control or for AEBSF-treated culture was found to
be significantly lower (Fig. 4E and F). Expression
of HMGCS1 in AEBSF treated cells was
indistinguishable from controls (+BGP, Fig. 4E),
whereas expression of COL1 A2 was lower in
AEBSF treated cells than controls (+BGP vs.
AEBSF, p=0.05, Fig. 4E). The qPCR results with
AEBSF are very similar to array results for DMP1,
procollagen XI alpha 1 chain, Phex, fibronectin,
and COL1 A2 (Table 2). The results for HMGCS1
were unexpected since its expression is tightly
regulated by SREBP-1 and SREBP-2 (42, 43) and
thus should be dependent upon SKI-1. Based on
qPCR results, mineralization in UMR106-01
cultures correlates most closely with the
expression of DMP1, COL11 A1, fibronectin, and
Phex (compare Figs. 2 and 4).
Activation of caspase-3 is regulated differently in
AEBSF and dec-RRLL-cmk treated cultures. As
first shown by Wang et al. (20, 21), activation of
SREBP-1 and SREBP-2 can be also mediated by
caspase-3. Caspase-3 and SKI-1 cleave these
factors at different sites producing different sized,
transcriptionally active N-terminal fragments (21,
22). We therefore tested whether a caspase-3/-7
specific inhibitor would also inhibit mineralization
of BMF. Interestingly, 10 and 20 µM Z-DEVDfmk had no significant effect on mineralization in
UMR06-01 cultures (Fig. 5A). By comparison,
100 µM AEBSF and 50 µM dec-RRLL-cmk
blocked mineralization by >85% (Fig. 5A).
To determine if caspase-3 was specifically
inactivated by Z-DEVD-fmk, the cytosolic
fraction of cell lysates was assayed using a small
fluorescent peptide substrate.
Caspase-7 is
predominantly membrane bound (44) under these
conditions and should have been removed by
centrifugation prior to assays.
Intracellular
caspase-3 catalytic activity was blocked by up to
80% by Z-DEVD-fmk and was also reduced
about 60% by dec-RRLL-cmk (Fig. 5B).
However, AEBSF had no effect. To establish if

dec-RRLL-cmk directly inactivated caspase-3, we
incubated recombinant caspase-3 with various
inhibitors for 30 min and then measured its
catalytic function. As shown in Figure 5C, 50 µM
dec-RRLL-cmk and 100 µM AEBSF were all
without effect—suggesting that the former acts
indirectly to block procaspase-3 activation.
In view of the differential gene expression
patterns observed with AEBSF and dec-RRLLcmk treated osteoblastic cultures (Fig. 4), we next
asked whether the amount of activated caspase-3
protein varied as a function of the inhibitor used.
UMR106-01 cultures were treated for 12 h with a
series of inhibitors as described in Figure 4. Cell
layers were then dissociated in hot SDS-8M urea
solution containing an excess of DTT, and
fractions were processed for Western blotting.
The total cellular content of activated 19 kDa
caspase-3 (45) was similar in mineralizing, unmineralized, and AEBSF–treated cultures (Fig.
5D). However, the caspase-3 content of decRRLL-cmk treated cultures was greatly reduced
(arrow, Fig. 5D). By comparison, blots processed
for control protein GAPDH gave similar band
intensities for all conditions (Fig. 5E).
These
results also suggest that activation of procaspase-3
is decreased in dec-RRLL-cmk treated cultures
compared with mineralizing, un-mineralized, and
AEBSF–treated cultures. Finally, the content of
19 kDa caspase-3 was noticeably higher in
cultures treated with 10 and 20 µM Z-DEVD-fmk
or Z-DEVD-OPH than in controls (arrowheads,
Fig. 5D).
Treatment of UMR106-01 cells with AEBSF or
with dec-RRLL-cmk alters the nuclear content of
SKI-1 activated transcription factors. To further
test if SKI-1 is required for activation of SREBP
and CREB/ATF family transcription factors which
are imported into the nucleus where they control
the expression of mineralization related genes, we
asked whether AEBSF or dec-RRLL-cmk reduced
the nuclear content of selected transcription
factors. Commonly, cells grown in 10% fetal
bovine serum have been used as a control for
caspase-3 activation since the serum cholesterol
leads to feedback inhibition of SKI-1 activation of
SREBPs. As a result, Western blotting was used
to identity the activating protease from the nuclear
sizes of activated transcription factors
To select which transcription factors to
investigate, we searched for conserved
transcription factor binding sites in the proximal
promoter regions of the PHEX, DMP1, FN1,
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COL11A1, COL1A2, and HMGCS1 genes using
the NCBI ECR Browser program. This analysis
revealed that consensus SRE and CRE sequences
exist in all of the six 5‘-proximal promoter regions
(not shown). Additionally, OASIS was shown
recently to be required for normal bone formation
(25, 26) and CREB-H (CREB3L3) represents a
CREB/ATF family member activated by SKI-1
(33). Expression of HMGCS1 is also regulated
primarily by SREBP-1 and SREBP-2 (42, 43).
Based on these findings, we focused our analyses
on a mix of SRE and CRE binding factors:
SREBP-1,
CREB-H
(CREB3L3),
OASIS
(CREB3L1), and SREBP-2.
UMR106-01 cells were plated as usual in 10%
fetal bovine serum (16) and at 64 h the media was
exchanged again for serum free media containing
either BGP alone (mineralizing conditions) or with
AEBSF, dec-RRLL-cmk, or Z-DEVD-fmk. Since
AEBSF and dec-RRLL-cmk required only 12 h to
reduce transcription of key mineralization genes
(see Fig. 4), we also stopped these cultures 12 h
after addition of inhibitors. Nuclear (Fig. 6) and
cytoplasmic (Fig. 7) fractions were then
immediately prepared for Western blotting.
Nuclear OASIS consisted of a 58 kDa SKI-1
activated form (OASIS panel, Fig. 6). This
assignment is consistent with the findings of
Omori et al. (46). The nuclear content of 58 kDa
OASIS was lower in both the AEBSF and decRRLL-cmk treated cultures (OASIS panel, Fig. 6).
Parallel controls with cytoplasmic extracts from
these same cultures were blotted against GADPH
and show that the observed changes were not due
to differences in sample loading (see Fig. 7).
These results indicate that AEBSF and dec-RRLLcmk both reduce the nuclear content of SKI-1
activated 58 kDa OASIS.
In contrast to OASIS, the nuclear content of
CREB-H did not change when AEBSF or decRRLL-cmk was included. Consistent with other
work with this antibody (32), a 42 kDa band (SKI1 activated) and doublet immunoreactive bands
containing 42 (SKI-1 activated) and 45 kDa
(caspase-3 activated) forms were detected in +FBS
cultures (CREB-H panel, Fig. 6). Thus, CREB-H
does not play a role in transcriptional changes
brought about by AEBSF or dec-RRLL-cmk (Fig.
4).
The nuclear content of 68 kDa activated
SREPB-2 was reproducibly decreased by both
AEBSF and dec-RRLL-cmk (SREBP-2 panel, Fig.
6). By comparison, nuclei from +FBS treated

cultures contained two closely spaced activated
SREPB-2 forms at 68 kDa (SKI-1 cleavage) and at
65 kDa (presumed to be cleaved by caspase-3).
The nuclear content of 68 kDa SREBP-2 is
reduced in cultures treated for 12 h with either
AEBSF or dec-RRLL-cmk.
SKI-1 activated SREBP-1 is also 68 kDa (20,
21) as shown in the mineralized control (SREBP-1
panel, Fig. 6). This band is largely absent in nonmineralizing conditions (No Phosphate, AEBSF,
and dec-RRLL-cmk) (SREBP-1 panel, Fig. 6). A
separate 58 kDa form of SREBP-1 (produced by
caspase-3) is present in +FBS cultures (20, 21).
In order to confirm the assignment of caspase3 cleaved transcription factors in Figure 6, we
isolated nuclear and cytoplasmic fractions from
osteoblastic cultures treated with 10 and 20 µM ZDEVD-fmk (Figs. 6 and 7). Our results show that
the nuclear content of CREB-H was increased in
cultures treated with 20 µM as compared with
+BGP alone (CREB-H, panel, Fig. 6). The 42
kDa size of the activated nuclear CREB-H form
whose content increased with 20 µM Z-DEVDfmk is consistent with its cleavage by SKI-1
(CREB-H panel, Fig. 6).
The effect of AEBSF and dec-RRLL-cmk inhibitors
on cytoplasmic SKI-1 activated transcription
factors. Cytoplasmic transcription factor analysis
provides a useful comparison with the nuclear
profiles presented in Figure 6. While carried out
in triplicate, single representative patterns are
presented in Figure 7. In contrast to the nuclear
results, the content of cytoplasmic 58 kDa OASIS
did not appear to correlate with the presence or
absence of inhibitors (Fig. 7).
Cytoplasmic
CREB-H consisted only of the SKI-1 activated 42
kDa form (33) and its content also did not vary in
the presence of inhibitors (CREB-H panel, Fig. 7).
In support of this assignment, the 42 kDa form
was absent from +FBS cultures.
In contrast to results with nuclear fractions,
analyses for cytoplasmic SREBP-2 revealed no
detectable band under any culture condition
(SREBP-2 panel, Fig. 7). Also, Western blotting
results for SREBP-1 yielded faint doublet bands at
68 (SKI-1 activated) and 58 kDa (caspase-3
activated) primarily in the FBS and Z-DEVD-fmk
treated cultures (SREBP-1 panel, Fig. 7).
However, the content of cytoplasmic SREBP-1
forms did not change with inhibitors. Finally, the
content of control protein GAPDH in cytoplasmic
extracts was constant among the different
conditions (GADPH panel, Fig. 7)
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Over-expression of SKI-1 activated SREBP-1
increases mineralization in UMR106-01 cultures.
To further test our hypothesis that osteoblastic
mineralization is dependent upon SKI-1 catalyzed
activation of SREBP and CREB/ATF family
transcription factors, we transiently overexpressed SKI-1 activated transcription factors
(SREBP-1a, SREBP-1c, SREBP-2, OASIS, and
CREB-H) in UMR106-01 cells. Plasmids were
used which express active transcription factors
retaining their nuclear import sequences and bZIP
DNA binding domains but missing their Cterminal membrane insertion sequences. All
plasmids were compared over the same
transfection dosage range which was optimized for
SREBP-1a in initial titration studies. Results are
presented visually in Figure 8 after fluorescent
staining for calcium mineral with Alizarin red S.
Over-expression of SREBP-1a resulted in a
significant increase in mineralized BMF
complexes compared with the non-plasmid control
or with cells transfected with OASIS, SREBP-2,
or SREBP-1c (Fig. 8). In a separate experiment,
SREBP-1a transfected cells contained 1.32-fold
more calcium in mineral deposits compared with
the non-plasmid control (p<0.05). Thus, overexpression of SREBP-1a was able to increase both
the number of biomineralization foci and the
amount of calcium mineral deposited by UMR
106-01 osteoblastic cells.
Also, CREB-H
transfected UMR 106-01 cells exhibited an
unusual morphological appearance. In contrast to
their usual dispersed appearance, BMFs in CREBH transfected cells were clumped together in
discrete regions which resembled mineralization
nodules seen in primary calvarial osteoblastic
cultures (see Fig. 3).

RRLL-cmk, a more specific SKI-1 inhibitor, on
expression of a subset of these genes revealed two
different outcomes. Phex, Dmp1, COL11A1, and
fibronectin were significantly reduced by both
inhibitors. COL1A2 and HMGCS1, a positive
control for SKI-1 activity (42, 43), were also
inhibited by AEBSF, but in contrast, expression
was increased by dec-RRLL-cmk relative to
mineralizing cultures. AEBSF and dec-RRLLcmk also reduced the nuclear content of activated
forms of OASIS, SREBP-1, and SREBP-2.
Because caspase-3 is known to activate SREBP-1
and SREBP-2 (20, 21), we also tested caspase3/capase-7 inhibitors; but Z-DEVD-fmk did not
block osteoblastic mineralization. However, the
activation and turnover of caspase-3 was
differentially modified depending upon the
inhibitor used, e.g., AEBSF, dec-RRLL-cmk, or ZDEVD-fmk. In contrast to AEBSF, the actions of
dec-RRLL-cmk represent the sum of its direct
actions on SKI-1 and indirect actions on caspase3.
Specifically, dec-RRLL-cmk reduced
intracellular caspase-3 activity by blocking the
formation of activated 19 kDa caspase-3. Finally,
over-expression of the SKI-1 activated forms of
SREBP-1a and of CREB-H in UMR106-01
osteoblastic cells increased the number of
mineralized foci and altered their local
distribution, respectively. These findings suggest
that expression of key genes (Phex, Dmp1,
COL11A1, and fibronectin) needed for
mineralization of osteoblastic cultures in vitro and
for bone formation in vivo are regulated by
SREBP and CREB/ATF family transcription
factors which require SKI-1 for their activation.
Intracellular and extracellular roles for SKI-1 in
osteoblastic mineralization.
Mineralization in
UMR106-01 cultures is a temporally synchronized
process and the first mineral crystals begin to
form 12 h after addition of exogenous phosphate
(13, 16, 17). If phosphate is not added or if
AEBSF is included, mineralization does not occur
(16, 17). AEBSF also blocks the fragmentation of
phosphoproteins BSP and BAG-75 which are
enriched within biomineralization foci, along with
inhibiting activation of procollagen C proteinase
enhancer protein. These results suggest that 105
kDa SKI-1 may be responsible for extracellular
proteolytic processing of secreted proteins within
biomineralization foci.
Since intracellular SKI-1 can also activate
transmembrane transcription factor precursors, we
carried out a whole genome array comparison of

DISCUSSION
We show here that mineralization, a property
of differentiated osteoblastic cells, is blocked by
covalent serine protease inhibitors AEBSF and
dec-RRLL-cmk in two osteoblastic culture
models. Since both inhibitors inactivate SKI-1, an
intracellular cis/medial-Golgi protease required for
activation of SREBP and CREB/ATF family
transcription factors, we examined the effect of
these inhibitors on gene expression. Short term
(12 h) treatment of osteoblastic cultures with
AEBSF decreased expression of 140 genes by 1.5to 3.0-fold including Phex, Dmp1, COL1A1,
COL1A2, COL11A1, and fibronectin.
A
subsequent comparison of AEBSF with dec-
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mineralizing versus AEBSF treated cultures.
Transcription of one-hundred forty genes was
reduced by 1.5- to 3-fold including Phex, Dmp1,
fibronectin, tenascin-N, tenascin-C, COL11A1,
COL1A1, and COL1A2. This result was then
validated when six of these genes were retested
with a more specific inhibitor of SKI-1, decRRLL-cmk,
using
a
qPCR
approach.
Furthermore, treatment of primary cultures of
transgenic DMP1-GFP calvarial cells with both
SKI-1 inhibitors not only blocked mineralization
but also inhibited GFP expression driven by a 10
kb DMP1 promoter. These findings demonstrate
for the first time that both a general and a specific
inhibitor of SKI-1 protease are able to
coordinately block transcription of this group of
mineralization related genes. Since inactivation or
deletion of the type XI collagen, type I collagen,
Dmp1, or Phex gene in vivo either causes a bone
deficiency phenotype or abnormal skeletal
development (2-5, 7, 8, 47, 48), we propose that
their combined reduced transcription is the
primary mechanism by which AEBSF and decRRLL-cmk inhibit mineralization in osteoblastic
cultures.
An additional unexpected stimulatory effect of
dec-RRLL-cmk on transcription of COL1A2
suggests that type I collagen may not be required
for initial mineral crystal nucleation and
deposition within BMF in the UMR106-01 model.
Rather, the blockage of procollagen C proteinase
enhancer protein activation by AEBSF (16), which
facilitates procollagen processing and fibril
assembly, leads us to propose that type I collagen
may function during subsequent propagation and
growth of initial mineral crystals in this model.
However, additional studies are needed to confirm
that these transcriptional changes reflect
differences in protein content.
Consideration of the effects of AEBSF and
dec-RRLL-cmk on gene expression in osteoblastic
cells immediately raises questions about whether
the promoters for fibronectin, DMP1, Phex,
COL11A1, and COL1A2 are regulated by SKI-1
activated transcription factors. A review of the
literature indicates that only the fibronectin and
positive control HMG-CoA-Synthase promoters
are known to be regulated by CREB and SREBP-2
(42, 43, 49, 50). However, ECR Browser searches
of the proximal 5-6 kb promoters for the human,
mouse, and rat fibronectin, Dmp1, Phex,
COL11A1, HMG-CoA-Synthase, and COL1A2
genes revealed conserved CRE and SRE

consensus sequences in all six promoters (data not
shown). While these assignments do not ensure
functionality, they are consistent with a common
role for SKI-1 in regulating transcription of
fibronectin, Dmp1, Phex, COL11A1, COL1A2, and
HMG-CoA-Synthase.
Analysis of nuclear transcription factor
content and size supports a role for SKI-1 in
mineralization. The nuclear content of 58 kDa
OASIS (CREB3L1) was decreased by AEBSF and
dec-RRLL-cmk. These results are consistent with
the known role of SKI-1 in activating OASIS.
Furthermore, changes in the nuclear OASIS
content brought about by AEBSF and dec-RRLLcmk correlates well with changes both in the
mineral content and with the expression of
COL11A1, FN, Phex, and Dmp-1 in osteoblastic
cultures.
AEBSF and dec-RRLL-cmk each affected the
nuclear contents of 68 kDa activated SREBP-1
and SREBP-2 differently. However, as expected,
caspase-3 cleaved forms of SREBP-1 (58 kDa)
and SREBP-2 (65 kDa) were enriched in +FBS
cultures. We presume that the cause for this
change is serum cholesterol inhibition mediated by
SCAP transport protein (41).
The response of SREBP-1 and SREBP-2 to ZDEVD-fmk was also different. While the rationale
for this finding is not clear, we suggest that
SREBP-1 could be activated by another caspase
not susceptible to this inhibitor or that turnover of
SREBP-1 and SREBP-2 may follow distinct
pathways.
In summary, the nuclear contents of activated
OASIS, SREBP-1, and SREBP-2 were all reduced
in AEBSF and dec-RRLL-cmk treated cultures
relative to mineralizing controls.
Since the
proximal promoters for fibronectin, COL11A1,
Phex, and Dmp-1 all contain SRE consensus
sequences (data not shown), our results suggest
that these inhibitors mediate their effects in
osteoblastic cells by blocking activation and
nuclear import of these SKI-1 activated
transcription factors leading to their diminished
nuclear contents and reduced transcription of
fibronectin, COL11A1, Phex, and Dmp-1.
Although fibronectin, COL11A1, Phex, and
Dmp-1 responded uniformly to the presence of
SKI-1 inhibitors, COL1A2 expression reacted
oppositely and increased over controls in response
to dec-RRLL-cmk. We speculate that regulation
of COL1A2 expression may be more complex and
that our results may reflect the actions of non-SKI-
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1 regulated transcription factors. However, it is
interesting to note that despite an increase in
COL1A2 expression, the overall effect of decRRLL-cmk was to block mineralization in
UMR106-01 cultures.
Effects of inhibitors on caspase-3 activation
and caspase-3 turnover. SREBP-1, SREBP-2, and
CREB transcription factors all appear to be subject
to proteasomal degradation (53, 54). Hirano et al.
(53) showed that SREBP-1 is ubiquitinated and
degraded in a manner consistent with the
proteasome and that its 3 h half-life was increased
when cells were treated with proteasome
inhibitors. Interestingly, when ubiquitination was
blocked, a small increase in nuclear SREBP-1 and
SREBP-2 content was observed along with an
increase in expression of HMG-CoA Synthase.
Three sites on SREBP-1 are important in terms of
its phosphorylation (Thr426 and Ser430 and
Ser434). Interestingly, phosphorylation occurs
after SREBP-1 binds to chromatin and is mediated
by glycogen synthase kinase3-beta (55, 56) (see
model, Fig. 9). Ubiquitin ligase Fbw7 is then
recruited to SREBP-1/promoter complexes
following its phosphorylation and catalyzes
ubiquitinylation of lysines with subsequent
proteasomal degradation of the modified SREBP1.
Based on this requirement and recent
identification of its nuclear localization sequence
(57), we have proposed that GSK3- can be
imported into the nucleus (see model, Fig. 9).
Because cytosolic caspase-3 can cleave
adenomatous polyposis coli protein and -catenin
(58, 59), we speculate that a decrease in the
intracellular content of activated caspase-3 could
lead to an increase in cytosolic complexes of
GSK3- with APC and -catenin (see model, Fig.
9). In this way, less GSK3- would then be
imported into the nucleus where it would
phosphorylate SREBP-1 (and possibly SREBP-2
and OASIS)—leading to their ultimate
proteasomal degradation. Thus, when caspase-3 is
inactivated by Z-DEVD-fmk or when activation of
caspase-3 is inhibited by dec-RRLL-cmk, more
GSK3- is predicted to remain complexed with
axin, catenin, and APC protein in the cytoplasm
(60), unable to phosphorylate transcription factors,
thus decreasing their turnover and transiently
increasing their nuclear concentration. In a similar
way, caspase inhibitors Z-VAD-fmk and ZDEVD-fmk were shown to block apoptosis by
suppressing NF-kappa B/p65 degradation, thereby

increasing nuclear translocation, DNA binding and
transcriptional activity (61).
Direct Western blotting analyses demonstrated
here that the level of activated 19 kDa caspase-3
subunit was reduced in dec-RRLL-cmk treated
cultures. These findings are consistent the report
by Park et al. (62) who showed that a serine
protease was required to activate caspase-3 during
apoptosis initiated by TNF-α. These results
suggest that SKI-1, a serine protease, can mediate
directly or indirectly the activation of procaspase-3
(see model, Fig. 9).
Although many studies have linked activation
of SREBP-1 and SREBP-2 with ER stress and
apoptosis (24), recent work has shown that SREBP
activation is also a characteristic of differentiated
cellular pathways such as membrane biogenesis
associated with phagocytosis (63), the secretion of
insulin by pancreatic beta cells (64), and the
transcription of the low density lipoprotein
receptor by endothelial cells induced by shear
stress (65). Also SREBP-1c (ADD-1) (66) is a
major positive regulator of fatty acid synthesis in
developing adipogenic tissues.
Our results
showing that SKI-1 inhibitors block mineralization
and the coordinated transcription of key
mineralization related genes support a requirement
for SKI-1 in the differentiation of osteoblastic
cells. Prior evidence for a non-apoptotic role for
caspase-3 in osteoblast differentiation was also
presented by Mogi and Togari (67) and Miura et
al. (68).
Our novel results demonstrate that a group of
genes required for normal bone formation share a
common transcriptional regulatory mechanism in
mineralizing osteoblastic cells (see model, Fig. 9).
Comparative Western blot analyses of the sizes
and contents of transcription factors SREBP-1,
SREBP-2, OASIS, and CREB-H in AEBSF or
dec-RRLL-cmk treated cultures further support the
role of SKI-1 in the activation of these
transcription factors, and, implicitly, in the
regulation of COL11A1, Phex, Dmp1, and
fibronectin. Careful analyses of the effects of
these inhibitors also indicate a hierarchical
relationship in which SKI-1 or another serine
protease inhibited by dec-RRLL-cmk, but not by
AEBSF, catalyzes the activation of caspase-3 in
osteoblastic cells. Our results indicate that the
differentiated phenotype of osteoblastic cells, and
possibly osteocytes, depends upon the nonapoptotic actions of SKI-1 to regulate the
synthesis of proteins (and lipids for vesicles)
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needed

to

assemble

and

mineralize

the

extracellular matrix of bone.
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SRE, sterol response element; CRE, cyclic AMP response element; S2P, site-2; BSP, bone sialoprotein;
BAG-75, bone acidic glycoprotein-75; SDS PAGE; sodium dodecyl sulfate polyacrylamide gel
electrophoresis; SAPE, streptavidin-phycoerythrin; GSK3- , glycogen synthase kinase-3-beta; PC,
proprotein convertase; AEBSF, 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride; SREBP, sterol
regulatory element-binding transcription factor; SCAP, SREBF cleavage activating protein; BMF,
biomineralization foci; FBS, fetal bovine serum; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide; Z-DEVD-OPH, Z- Asp-Glu-Val-Asp-[2,6-difluorophenoxy]-methyl
ketone; Z-DEVD-fmk, Z-Asp-Glu-Val-Asp-fluoromethyl ketone; dec-RRLL-cmk, decanoyl-Arg-ArgLeu-Leu-chloromethyl ketone; FGF23, fibroblast growth factor 23; and, ICER, inducible cyclic AMP
early repressor.
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FIGURE LEGENDS
Figure 1. Activated 105 kDa SKI-1 is localized to extracellular calcified biomineralization foci in
osteoblastic cultures.
A, Comparative Western blotting of laser micro dissected biomineralization foci with total cell
layer extracts from osteoblastic cultures with anti-C-terminal SKI-1 antibodies. UMR106-01
osteoblastic cells were grown on glass slides, allowed to mineralize as described (13) and resultant
mineralized biomineralization foci were isolated by laser micro dissection after staining with Alizarin red
S dye; and isolated BMF and total cell layer fractions were then extracted and subjected to Western
blotting as described previously (16). Six micrograms of protein was applied to each lane. No
immunoreactive bands were detected in extraction buffer alone controls (Buffer, Fig. 1A). Numbers of
left margin refer to estimated molecular weights of immunoreactive bands.
KEY:
BMF,
biomineralization foci isolated by laser micro dissection; CL-Min, total cell layer from mineralized
culture; CL-UnMin, total cell layer from non-mineralized culture; Buffer, control for extraction buffer.
B, Comparative Western blotting of cell layer extracts and media fractions from mineralized,
AEBSF-inhibited, and non-mineralized osteoblastic cultures. Media was removed and the residual
cell layer fraction was then extracted sequentially with 0.05 M EDTA and with 8M urea/0.5% CHAPS as
described by Huffman et al. (16). Equivalent amounts of each fraction (urea/CHAPS extract, EDTA
extract, and media) were subjected to Western blotting with anti-C-terminal SKI-1 antibodies using
chemiluminescent detection. Numbers of left margin refer to estimated molecular weights of
immunoreactive bands. KEY: BGP, with 6.5 mM -glycerolphosphate; and, AEBSF, with 100 µM 4(2-aminoethyl) benzene sulfonyl fluoride hydrochloride.
Figure 2. SKI-1 specific inhibitor, dec-RRLL-cmk, like AEBSF, specifically inhibits mineralization
in UMR106-01 osteoblastic cultures.
Error bars refer to standard deviations; probabilities were determined by a one-way ANOVA with a
Student-Newman-Keuls multiple comparison test.
A, Titration of dec-RRLL-cmk demonstrates its capacity to completely block mineralization
without affecting cell viability. Osteoblastic cells were grown as usual and treated for 24 h under
mineralizing conditions (see METHODS) with different concentrations of inhibitor. Mineralization was
assayed with a colorimetric calcium assay by reference to a standard curve; cell viability was determined
using the MTT assay.
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B, Side-by-side comparison reveals dec-RRLL-cmk and AEBSF both
mineralization in culture. KEY: +BGP, plus -glycerolphosphate; -BGP, minus
dec-RRLL-cmk, 40 µg/ml inhibitor; and, AEBSF, 100 µM inhibitor.
C, Furin peptide inhibitor dec-RVKR-cmk is without effect on mineralization.
-glycerolphosphate; -BGP, minus -glycerolphosphate; dec-RVKR-cmk, range of
8 to 75 micromolar; and, DMSO, high and low represent solvent controls.

completely block
-glycerolphosphate;
KEY: +BGP, plus
concentrations from

Figure 3. SKI-1 inhibitor dec-RRLL-cmk also blocks mineralization of primary mouse calvarial
osteoblastic cells.
Primary mouse calvarial cells from transgenic DMP1 GFP mice (34) were harvested by a conventional
sequential collagenase digestion protocol and plated as noted in METHODS. The media was changed at
three day intervals starting on day 3 after plating. Some cultures were treated with SKI-1 inhibitors.
Scale bars=375 microns
A, Control calvarial cells produced mineralized nodules on day 12 after plating. Mineralized
nodules were detected by fluorescence microscopy after staining the culture with 10 µg/ml Alizarin red S
dye. Green fluorescent signal represents GFP protein expressed under control of the 10 kb Dmp1
promoter. Yellow represents areas of overlap of mineral (red) and GFP signals. Arrows demark
mineralized areas which also express GFP protein.
B, Dec-RRLL-cmk blocks the mineralization of primary calvarial cells as well as expression of
GFP protein. Cells were treated continuously from day 3 until day 12 with 8 µM dec-RRLL-cmk
inhibitor and then the cultures were imaged by fluorescence microscopy as in A.
C, AEBSF inhibits the mineralization of primary calvarial cells as well as expression of GFP
protein. Cells were treated continuously from day 3 until day 12 with 10 µM AEBSF inhibitor and then
the cultures were imaged by fluorescence microscopy as in A.
Figure 4. Dec-RRLL-cmk and AEBSF block expression by UMR106-01 osteoblastic cells of key
genes required for mineralization and for normal bone formation.
Total RNA was isolated from replicate cultures (n=6/condition) treated for 12 h with β-glycerolphosphate
with or without inhibitors and converted into cDNA with reverse transcriptase (see METHODS).
Quantitative PCR was carried out using primer sets for individual genes and the relative expression for
each gene was plotted as a percentage of that expressed by mineralized control cultures. Error bars refer
to standard deviations and probabilities were calculated using a one-way ANOVA test. KEY: +BGP,
control cultures treated with mineralizing conditions (6.5 mM β-glycerolphosphate); +AEBSF+BGP,
cultures treated for 12 h with 100 µM AEBSF under mineralizing conditions; +Dec-RRLL-cmk+BGP;
cultures treated for 12 h with 40 µM dec-RRLL-cmk under mineralizing conditions.
A-F, Quantitative PCR results for Dmp1, COL11A1, fibronectin, Phex, COL1A2, and HMGCS1 genes.
Figure 5. Dec-RRLL-fmk partially blocks activation of caspase-3 although caspase-3 inhibitors do
not inhibit osteoblast-mediated mineralization.
UMR106-01 cultures were treated with β-glycerolphosphate with or without inhibitors and then cell layer
fractions were assayed for soluble caspase-3 activity, mineral calcium content, and caspase-3 protein
content by Western blotting as described in EXPERIMENTAL PROCEDURES. The direct effects of
inhibitors on recombinant caspase-3 was analyzed separately. Error bars represent standard deviations
and probabilities were tested with a one-way ANOVA test using a Student-Newman-Keuls multiple
comparison test.
KEY: Mineralized, cells treated with β-glycerolphosphate; Un-mineralized, no β-glycerolphosphate;
+AEBSF, cells treated with 100 µM inhibitor and β-glycerolphosphate; +Dec-RRLL-cmk, cells treated
with 40-50 µM inhibitor and β-glycerolphosphate; + 10 Z-DEVD-fmk, cells treated with 10 µM inhibitor
and β-glycerolphosphate; + 20 Z-DEVD-fmk, cells treated with 20 µM inhibitor and βglycerolphosphate; + 10 Z-DEVD-OPH, cells treated with 10 µM inhibitor and β-glycerolphosphate; +
20 Z-DEVD-OPH, cells treated with 20 µM inhibitor and β-glycerolphosphate.
All results are
representative of at least duplicate experiments.
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A, Treatment of UMR106-01 osteoblastic cultures with Z-DVED-fmk does not block
mineralization. The average amount of calcium deposited in biomineralization foci was then determined
colorimetrically (n=6).
B, Z-DVED-fmk and Dec-RRLL-cmk lead to significant reductions in intracellular caspase-3
activity. Soluble intracellular caspase-3 activity was extrapolated from kinetic reaction plots; the
averaged data is plotted as Arbitrary Fluorescence Units/h (n=6).
C, Dec-RRLL-cmk does not directly inactivate recombinant caspase-3. Activity was extrapolated
from kinetic reaction plots and is plotted as the average nmoles AMC released/h/ng protein (n=6).
D, Western blot analysis for precursor and activated caspase-3 forms. The amount of procaspase-3
32 kDa and of intracellular activated 19 kDa caspase-3 subunit varies depending upon the protease
inhibitor treatment. The total cell layer of treated UMR106-01 cultures was extracted with hot SDS/urea
sample buffer and subjected to Western blotting with anti-caspase-3 antibodies. The pattern is
representative of triplicate experiments. Arrow denotes decreased 19 kDa band in dec-RRLL-cmk
treated cells; arrowheads demark increased 19 kDa band content in cells which were treated with
caspase-3 Z-DEVD-fmk or Z-DEVD-OPH inhibitor.
E, Western blot for intracellular GAPDH control. The cell layers in triplicate wells were extracted
with hot SDS/urea sample buffer and subjected to Western blotting with anti-GADPH antibodies.
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Figure 6. AEBSF, dec-RRLL-cmk, and Z-DEVD-fmk inhibitors alter the nuclear content of SKI-1
activated transcription factor(s).
Cultures were treated for 12 h under mineralizing conditions with different protease inhibitors and the
nuclear fraction was then isolated. All culture conditions were carried out in triplicate and Western
blotting results for OASIS, CREB-H, SREBP-1, and SREBP-2 depicted are representative of these
replicates. Cytoplasmic fractions were also isolated from these same cultures and Western blots for
control protein GAPDH are shown in Figure 7. All lanes shown for each different transcription factor
were imaged similarly and at the same time. KEY: Mineralizing, cells treated with mineralizing
conditions (6.5 mM β-glycerolphosphate); No Phosphate, no -glycerolphosphate added; +AEBSF,
cells treated with 100 µM inhibitor; +Dec-RRLL-cmk, cells treated with 40 µM dec-RRLL-cmk; 10 ZDEVD-fmk, cells treated with 10 µM inhibitor; 20 Z-DEVD-fmk, cells treated with 20 µM inhibitor.
OASIS panel, nuclear fractions subjected to Western blotting for OASIS.
CREB-H panel, nuclear fractions subjected to Western blotting for CREB-H.
SREBP-1 panel, nuclear fractions subjected to Western blotting for SREBP-1.
SREBP-2 panel, nuclear fractions subjected to Western blotting for SREBP-2.
Figure 7. Cytoplasmic contents of selected SKI-1 activated transcription factors.
Cultures were treated for 12 h under mineralizing conditions with different protease inhibitors and then
the cytoplasmic fraction was isolated from each using a commercial kit. All culture conditions were
carried out in triplicate and results shown are representative of these replicates and GAPDH Western blots
were used to control for intra-culture variations. Nuclear fractions were also isolated from these same
cultures. All lanes shown on each panel below was imaged similarly and at the same time.
KEY: Mineralizing, cells treated with 6.5 mM
-glycerolphosphate; No Phosphate, no glycerolphosphate added; +AEBSF, cells treated with 100 µM inhibitor; +Dec-RRLL-cmk, cells treated
with 40 µM dec-RRLL-cmk; 10 Z-DEVD-fmk, cells treated with 10 µM inhibitor; 20 Z-DEVD-fmk,
cells treated with 20 µM inhibitor.
OASIS panel, cytoplasmic fractions subjected to Western blotting for OASIS.
CREB-H panel, cytoplasmic fractions subjected to Western blotting for CREB-H.
SREBP-1 panel, cytoplasmic fractions subjected to Western blotting for SREBP-1.
SREBP-2 panel, cytoplasmic fractions subjected to Western blotting for SREBP-2.
GAPDH panel, cytoplasmic fractions subjected to Western blotting for GAPDH.
Fig. 8. Over-expression of activated forms of SREBP-1a and CREB-H in UMR106-01 cells
increases the number and clustering of mineralized biomineralization foci, respectively.
Forty hours after plating, cells were transiently transfected with plasmid in the presence of Metafectamine
Pro and grown under standard mineralizing conditions (see METHODS). At 88 h, cultures were fixed
with 70% ethanol, stained with Alizarin red S dye, and photographed using a fluorescence microscope.
Mineralized BMF appear as white dots or clusters (arrows) under these conditions. Over-expression with
activated OASIS, SREBP-1c, and SREBP-2 was without effect and indistinguishable from non-plasmid
control cultures. Calcium assays revealed that SREBP-1c transfected cells deposited 1.32-fold more
hydroxyapatite than non-plasmid control cells (p<0.05). Scale bar=500 µm.
Figure 9. Proposed intracellular mechanism of AEBSF, Dec-RRLL-cmk, and Z-DEVD-fmk effects
on gene expression by osteoblastic cells.
Steps depicted in bold type are those suggested from experimental data presented here. Other parts of the
model are derived from a variety of literature sources referenced in the Discussion section.
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TABLE 1
The effect of Inhibitors on Total Cellular SKI-1 Peptidase Activity
Culture Condition
Peptidase Activity +/- STD
Percent of
(Arbitrary fluorescence units/ h /
Control
culture well) x 1000
Mineralizing Control (+BGP)
1616 +/- 58.3
100% +/- 3.6
+100 µM AEBSF +BGP
1161 +/- 145.0
71.8% +/- 12.5
+50 µM Dec-RRLL-cmk +BGP
986 +/- 125.6
61.0% +/- 12.7
+20 µM DEVD-OPH +BGP
1727 +/- 67.9
106.8% +/- 3.9
+75 µM Dec-RVKR-cmk +BGP
1807 +/- 119.0
111.8% +/- 6.6

Statistical
Significance

p<0.05
p<0.05

Replicate cultures (n=6) were stopped 8 h after the addition BGP and SKI-1 assays carried out on total
cell lysates as described in EXPERIMENTAL PROCEDURES. Data analyzed using a 1-way ANOVA
with a Student-Newman-Keuls multiple comparison test. Representative of duplicate experiments.

TABLE 2
AEBSF blocks transcription of a number of key mineralization
related genes in whole array study with UMR106-01 cells
Fold Change Gene
Description
symbol
-1.58
Hsd17b11
hydroxysteroid (17-beta) dehydrogenase 11
-1.59
Senp7
SUMO1/sentrin specific protease 7
-1.64

Adamtsl1

AdamTS1 like protease

-1.66

Phex

-1.67
-1.77

Casp4
Enpp3

Phosphate regulating gene with homologies to
endopeptidases on the X chromosome
Caspase 4
Alkaline phosphodiesterase

-1.85

Fbn2

Fibrillin 2

-1.90

Enpp2

-1.90

Tnc

Ectonucleotide pyrophosphatase/
phosphodiesterase 2
Tenascin C

-1.91

pColA1 (I)

Procollagen, type I, alpha 1 chain

-1.94

Mitf

Microphthalmia-associated transcription factor

-1.97

Atp1a2

ATPase, Na+K+ transporting, alpha 2

-1.97

Tnn

Tenascin N

-1.98

Fn

Fibronectin 1

-2.10

Scn1a

Sodium channel voltage-gated, type 1 alpha

-2.13
-2.18
-2.28
-2.37
-2.50
-2.55
-2.99

pColA1(XI)
pColA2(I)
Acss2
Serpini1
DMP-1
pColA2(I)
Matn3

Procollagen, type XI, alpha 1 chain
Procollagen, type I, alpha 2 chain
Acyl CoA synthetase short chain family member 2
Serine (cysteine) peptidase inhibitor
Dentin matrix protein-1
Procollagen, type I, alpha 2 chain
Matrilin 3
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